Table 2.
Association between exposure to prolactin‐inducing antipsychotics and risk of breast cancer, specified by exposure pattern within the entire follow‐up‐period, excluding the last year prior to the index date
| Exposure group | Cases | Controls | Adjusted ORa | Adjusted ORb |
|---|---|---|---|---|
| Nonuse | 55 409 | 555 957 | 1.0 (ref.) | 1.0 (ref.) |
| Ever use | 4798 | 46 156 | 1.04 (1.01–1.08) | 1.00 (0.97–1.04) |
| Long‐term use c | 693 | 5659 | 1.23 (1.14–1.33) | 1.18 (1.06–1.32) |
| Cumulative use c | ||||
| 0–4999 mg | 3756 | 37 619 | 1.00 (0.97–1.04) | 0.97 (0.94–1.01) |
| 5000–9999 mg | 349 | 2878 | 1.21 (1.09–1.36) | 1.19 (1.05–1.34) |
| 10 000–19 999 mg | 243 | 2131 | 1.15 (1.01–1.32) | 1.11 (0.95–1.29) |
| 20 000–49 999 mg | 246 | 1993 | 1.24 (1.09–1.42) | 1.27 (1.07–1.50) |
| ≥50 000 mg | 204 | 1535 | 1.33 (1.15–1.54) | 1.27 (1.01–1.59) |
OR, odds ratio
a
Adjusted for age and calendar‐time (by design; risk‐set matching).
b
Fully adjusted model, see section ‘Analytical variables’.
c
Exposure to different antipsychotics was standardized using olanzapine equivalents 38. Long‐term use was defined as a cumulative exposure of 10 000 mg olanzapine.